Since recreational cannabis was legalized in Canada in October 2018, most investors looking to catch a ride on the green wave, bumpy as it may be, have focussed on the opportunities available at home and in the United States. But while Canada may have taken the biggest leap into the legal realm, it is not the only country in which attitudes toward cannabis are changing. Here’s a look at five internationally focussed stocks that investors can look to for exposure to the emerging global cannabis industry.

Although regulatory reform has occurred across Europe, many patients still experience barriers regarding accessing medical cannabis, here Prohibition Partners explores further.

Prohibition Partners explains how legislation intended to improve availability of accessing medical cannabis for patients is being hindered by a lack of education in clinicians and regulators.

Five companies have applied to Denmark’s government for licenses to sell and export medicinal cannabis.

The country is a quarter of the way through a four-year medicinal cannabis trial, but some of the usual suspects are not waiting for the outcome to slow down their Danish strategy in what is emerging as a key market.

Aurora Nordic, Medican, Medical Cannabis Denmark, Schroll Medical/Aphria, and Spectrum Cannabis Denmark (part of Canopy Growth) are hoping to gain approval for bulk manufacturing licenses.

Denmark is not a European Union state, but is part of the European Economic Area and firms situated there can export to the bloc, which with a population of 700m has the potential to be the world’s largest market, according to cannabis intelligence researchers.

The marijuana industry is growing like a weed. According to various Wall Street prognostications, the global cannabis industry could be generating upwards of $50 billion to $75 billion in annual sales roughly one decade from now. That's a boatload of cash, and all the more reason for pot growers to double down on capacity expansion.

Although there are 11 growers that are currently on pace for more than 100,000 kilograms in peak annual output, according to their respective management teams, none stands out more than Alberta-based Aurora Cannabis (NYSE:ACB).

Indiva will have the exclusive right to all cannabis-related production. Subject to applicable regulatory approvals, Indiva will also leverage the Denmark license for the importation of EU-GMP cannabis into the Danish and European markets.

Indiva has identified Europe as a key emerging market in cannabis, estimated at some $80 -100 billion at maturity1. Europe is home to greater than 500 million people and the growing acceptance of medical cannabis is leading to significant growth in registered patients.

Medical cannabis will soon be a state-subsidized medication for certain patients in Denmark, writes Calvin Hughes.

New laws spawn a growth in the industry as 12 permits are issues, with three more impending.

Denmark will soon become one of the largest medical cannabis producers in Europe.

Since December 2017, the Laegemiddelstyrelsen medicines agency has issued 12 permits to companies to produce medical cannabis.

The authorisations followed last year’s parliamentary approval of a four-year trial for doctors to prescribe medical cannabis to patients, which began on January 1.

Since this approval, 17 companies have sought the right to produce medical cannabis in Denmark. Two were rejected and three are still awaiting a decision.